Brain Corp Continues European Growth, Demonstrates ‘Inventory Scan’ Technology with Tennant Company, a First-of-its-kind Robotic Solution for Automated Analytics in Retail
28.4.2022 11:00:00 EEST | Business Wire | Press release
Brain Corp, an artificial intelligence (AI) company creating transformative core technology in robotics, and Tennant Company, today announced the European demonstration of Inventory Scan, a powerful new data capture accessory that will be fitted to Tennant’s autonomous floor scrubbers to autonomously scan and report key detail on in-store inventory.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220428005188/en/
Brain Corp Demonstrates ‘Inventory Scan’ Technology with Tennant Company at Interclean (Photo: Business Wire)
"By adding Inventory Scan to new or existing robotic scrubber fleets, retailers are immediately able to access critical in-store inventory data in near real-time," said Dave Ross, Vice President of Business Development at Brain Corp. "Knowing where an item is, if it’s in stock, if it’s in the correct location, if the price is accurate, and more allows managers to operate stores with a new level of efficiency while providing optimal shopping experiences for their customers. Based on the success we’ve seen in the US with the technology, we are excited to get feedback from those in the European market.”
Utilizing a first-of-its-kind, multi-purpose design, the powerful new scanning accessory will be fitted to Tennant’s floor scrubbers powered by Brain Corp’s BrainOS autonomy software platform. The new, cloud-connected Inventory Scan tower is able to capture data as it moves autonomously around the store. Reports are then delivered to the store managers, providing numerous insights including: verification of pricing accuracy, planogram compliance, product stock levels and product localization. Each function negates the need for time-consuming and potentially inaccurate manual processes, which often lead to lost revenue opportunities, waste caused by overordering and not enough attention given to shoppers.
“The new integrated inventory analytics accessory is filling a much-needed AI and data process gap for retailers,” said Maggie Koester, Global Product Manager at Tennant Company. “What makes this solution compelling is the ability to integrate with retailers’ inventory management systems utilizing their existing floor scrubbers. By adding data collection functionality to these machines, we are dramatically improving how stores operate. Inventory Scan allows retailers to be more efficient and effective by reducing the disruption of labor-intensive manual approaches. Our vision is that data collection and floor care become fully automated so our customers can focus on managing their businesses.”
Interclean 2022 to Host the Unveiling of the Technology in Amsterdam
Inventory Scan will have its European introduction on May 10-13, 2022 at the RAI Centre in Amsterdam, on Brain Corp stand - Hall 7, Booth 108.
"This new product marks the beginning of realizing the next phase in our company's vision and continued growth in Europe as well as the US," said Dr. Eugene Izhikevich, CEO of Brain Corp. "We are actively taking BrainOS-powered robots from primarily task-oriented machines to in-store data acquisition platforms. This delivers critical insights and this will add significant ROI for European retailers as we continue to expand our activity in Europe and beyond."
Brain Corp Sees 100% Year-on-year Growth in European Countries Deploying BrainOS-powered Robots
Partnering with many of the world’s leading OEMs (Original Equipment Manufacturers) including Minuteman, Karcher, Nilfisk and Tennant, autonomous robotic scrubbers, powered by Brain Corp’s AI operating system BrainOS®, are now operational across multiple sectors in 16 European countries.
New countries seeing robotic deployments include Belgium, Denmark, Finland, Luxembourg, Norway and Switzerland. Countries implementing the largest numbers of autonomous robots include France, Spain, Portugal, Italy, Germany, the UK, and the Netherlands.
“There’s no doubt that we’re starting to see the tipping point where the integration of robotics with human teams has gone beyond a novelty and become a practical solution for maintaining sustainable operations,” said Michel Spruijt, SVP International Business at Brain Corp. “We’re seeing significant increases in demand across multiple industry sectors which have been impacted most severely by labor shortages and increased operational strain as a result of the pandemic. Autonomous robotics have proven themselves to be a very effective and welcome solution to these growing problems.”
In 2021, the BrainOS®-powered fleet of autonomous mobile robots hit a major milestone of 500 million square feet covered (46.45 million square meters) autonomously in Europe. In total, over 46,000 hours were given back to workers during the year with the most significant growth coming within retail, logistics, and warehousing sectors.
About Brain Corp
Brain Corp is the global leader in robotic AI software that powers the largest fleet of autonomous mobile robots (AMRs) operating in commercial public spaces. Global OEM partners use the company’s cloud-connected platform, BrainOS®, to create scalable, self-driving robots that are used by end customers to clean floors, move inventory, and sense environmental data - turning manual operations into automated workflows. Fortune 500 brands across multiple verticals benefit from the growing portfolio of BrainOS®-powered robots and our industry-leading privacy, safety and efficiency tools that make managing and scaling automation easier. Brain Corp currently powers more than 20,000 AMRs, representing the largest fleet of its kind in the world.
For more information, visit www.braincorp.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220428005188/en/
Contact information
Josh Stanbury | josh@sjspr.co | 416-628-7441
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros to Present at BIO International Convention 202615.6.2026 08:00:00 EEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 07:05:00 EEST | Press release
Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
